Janney Montgomery Scott’s Lipocine LPCN Stock Holding History

Janney Montgomery Scott’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-635	Closed	-$17K	–	2029
2018 Q1	$17K	Buy	+635	New	+$17.7K	﹤0.01%	1931

Other funds holding LPCN

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Janney Montgomery Scott's LPCN Position: Q2 2018 in Review

Janney Montgomery Scott sold out of Lipocine (LPCN) in Q2 2018, closing a stake of 635 shares — an estimated $17K sold.

Janney Montgomery Scott first reported a position in LPCN in Q1 2018 and held it in 1 quarter. The position peaked at $17K in Q1 2018. 30 funds tracked by Wall St. Rank hold LPCN as of Q2 2018.

Janney Montgomery Scott reported no remaining Lipocine position as of Q2 2018 after selling out during the quarter.
Janney Montgomery Scott sold 635 Lipocine shares in Q2 2018, an estimated $17K.
Janney Montgomery Scott first reported a position in Lipocine in Q1 2018 and held it in 1 quarter.
Janney Montgomery Scott's Lipocine position peaked at $17K in Q1 2018.
30 funds tracked by Wall St. Rank held Lipocine as of Q2 2018.

Based on Janney Montgomery Scott's 13F filing for Q2 2018, filed 24 Jul 2018.